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INTRODUCTION: Antibiotic use has emerged as a risk factor for colorectal neoplasia and is hypothesized as a contributor

to the rising incidence of colorectal cancer under age 50 years or early-onset colorectal cancer (EOCRC).
However, the impact of antibiotic use and risk of EOCRC is unknown.
METHODS:

We conducted a population-based case-control study of CRC among individuals aged ‡18 years in the
Epidemiology Strengthened by histoPathology Reports in Sweden (ESPRESSO) cohort (2006–2016). The
primary outcome was EOCRC. A secondary outcome was CRC at any age. Incident CRC was pathologically
confirmed, and for each, up to 5 population-based controls were matched on age, sex, county of residence,
and calendar year. We assessed prescriptions until 6 months before CRC diagnosis. Conditional logistic
regression was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs).

RESULTS:

We identified 54,804 cases of CRC (2,557 EOCRCs) and 261,089 controls. Compared with none,
previous antibiotic use was not associated with EOCRC risk after adjustment for potential confounders
(aOR 1.06, 95% CI: 0.96, 1.17) with similarly null findings when stratified by anatomic tumor site. In
contrast, previous antibiotic use was weakly associated with elevated risk for CRC at any age (aOR 1.05,
95% CI: 1.02, 1.07). A potential but modest link between broad-spectrum antibiotic use and EOCRC
was observed (aOR 1.13, 95% CI: 1.02, 1.26).

DISCUSSION:

We found no conclusive evidence that antibiotics are associated with EOCRC risk. Although antibiotic
use was weakly associated with risk of CRC at any age, the magnitude of association was modest, and
the study period was relatively short.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A737
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INTRODUCTION
Contrasting with overall declines in colorectal cancer (CRC) incidence, rates have increased dramatically among those aged
20–49 years (1), particularly in Sweden with an annual percent
change of 2.8% from 1991 to 2015 for ages 20–39 years and 1.2%
for ages 40–49 years, respectively (2). Early-onset CRC (EOCRC)
or CRC before age 50 years is detected at more advanced stages
than later-onset CRC (CRC after age 50 years) with more

aggressive tumors and greater years of life lost (3–6). This concerning trend has led to updated guidelines from both the
American Cancer Society and draft recommendations from the
United States Preventative Services Task Force advising averagerisk screening begin at age 45 years rather than 50 years (7,8).
Although these changes could lead to the earlier detection of
colorectal neoplasia, primary disease prevention—the cornerstone of most public health eﬀorts—is relatively underexplored in
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EOCRC. Despite previous investigations implicating obesity
(9,10), a sedentary lifestyle (11), and metabolic syndrome (12) as
potential targets for intervention, the identiﬁcation of other
modiﬁable risk factors and how they might diﬀer from later-onset
CRC remain a high unmet need.
Because EOCRC has been rising predominantly in Western
populations and developing regions in Asia (13), increased sanitation and the widespread use of broad-spectrum antibiotics
(14–16) have been proposed as reasons for why this emerging
disparity in disease burden is becoming more apparent. Previous
studies have demonstrated that up to ⅓ of all antibiotic dispensations may be inappropriate (17,18). Although campaigns to
encourage antibiotic stewardship have seen recent success, relatively modest decreases in prescribing patterns have only been
apparent in the last decade, likely too recent to have inﬂuenced
the alarming upward trends in EOCRC (19–22), even in countries
like Sweden where a strategic program to decrease antibiotic
usage has been in place since the early 1990s (23–26). More
dramatic decreases in antibiotic usage may be possible if informed
by compelling data on how it might inﬂuence risk of gastrointestinal (GI) diseases, including CRC.
With greater appreciation for the critical role of the gut
microbiome in GI disease development, so too has concern that
antibiotics that perturb these microbial communities generate the
dysregulated host/microbial interactions that promote early colorectal carcinogenesis. Despite this compelling rationale, the
relationship between antibiotic usage and subsequent risk of
EOCRC remains to be elucidated. Thus, to our knowledge, we
conducted the largest investigation exploring the potential association between antibiotic use and risk of EOCRC in a large nationally representative case-control study in Sweden.

METHODS
Study population

In Sweden, access to health care is universal and tax funded. This
includes prescription drug coverage (27). The Swedish National
Board of Health and Welfare has collected patient-level information on hospital discharges nationwide since 1987 in the
Swedish Patient Register (28). Each record includes sex, date of
birth, dates of hospital admission, and procedural and discharge
diagnoses by International Classiﬁcation of Diseases (ICD) code
(Figure 1). In 2001, this registry was expanded to include outpatient specialty care, including visits to gastroenterology or
oncology providers. The positive predictive value for most diagnoses in this register ranges between 85% and 95% (28).
We integrated these national registry data with the Epidemiology Strengthened by histoPathology Reports in Sweden
(ESPRESSO) study (29). Brieﬂy, the ESPRESSO study is a comprehensive data harmonizing eﬀort involving all 28 pathology
laboratories in Sweden and any GI pathology reports generated
for clinical care or research purposes between 1965 and 2017. This
consortium has enrolled more than 2.1 million unique individuals with detailed information on GI topography (i.e., the anatomic location of the obtained tissue), morphological appearance,
and pathologist’s diagnostic impression. As previously described
(29), at the time of ESPRESSO inclusion, individuals were paired
with up to 5 controls from the general population, matched on the
basis of age, sex, calendar year, and county. Finally, since July
2005, the Swedish Prescribed Drug Register has collected information on all medications, including antibiotics, prescribed to
Clinical and Translational Gastroenterology

the entire Swedish population, including date of redemption,
amount dispensed, and dose allotted (29,30).
Patient-level information from ESPRESSO and both national
registries (Patient Register and the Prescribed Drug Register) was
linked by a unique personal identity number assigned at birth or at
the time when permanent residence was established. To ensure
adequate time at risk (e.g., to allow for accrual of antibiotic dispensations), we deﬁned the study baseline as January 1, 2006. Thus, our
study encompasses all consecutive eligible patients for the period of
overlap during which the National Patient Register, the ESPRESSO
study, and the Prescribed Drug Register were each actively enrolling
plus a 6-month lead-in period (January 1, 2006, to December 31,
2016). This investigation was approved by the Stockholm Ethics
Review Board (Protocol 2014/1287-31/4). Because of the strict
registry-based nature of the study, informed consent was waived.
Ascertainment of outcomes

Our primary outcome was incident CRC diagnosed under age 50
years. An a priori secondary outcome was CRC at any age. Using
predeﬁned anatomic and histologic criteria, as well as the attending pathologist’s diagnostic impression (see Supplementary
Table 1, Supplementary Digital Content 1, http://links.lww.com/
CTG/A737), we identiﬁed individuals in the ESPRESSO study
with GI tract histopathology compatible with the diagnosis of
incident CRC from January 2006 to December 2016. We then
cross-referenced potential cases and the entirety of their inpatient
and outpatient records in search of at least 1 ICD code consistent
with CRC, thus requiring both compatible histopathology and
registry-level case conﬁrmation. We abstracted information on
the date of diagnosis and tumor location with CRCs of the cecum,
ascending colon, hepatic ﬂexure, transverse colon, and splenic
ﬂexure deﬁned as proximal, descending or sigmoid colon deﬁned
as distal, and rectum or rectosigmoid junction deﬁned as rectal,
respectively. We excluded those with CRC-compatible pathology
or ICD diagnostic coding before our study baseline (January
2006). The date of CRC diagnosis was deﬁned as the earliest
among the dates of relevant pathology ﬁndings and the ﬁrst appearance of a CRC-related diagnosis code (Figure 1).
Ascertainment of primary exposure and other covariates

Cumulative antibiotic usage before CRC diagnosis or matching
(primary exposure) was deﬁned as the cumulative sum of antibiotic dispensations. To account for the possibility of reverse
causation or antibiotic therapy prescribed for symptoms related
to undiagnosed CRC, we did not count dispensations in the 6
months before CRC diagnosis/matching. Antibiotic use was
assessed in the Swedish Prescribed Drug Register and categorized
using established World Health Organization Anatomical
Therapeutic Chemical (ATC) codes for the therapeutic subgroup
of antibacterials approved for systemic usage (see Supplementary
Table 2, Supplementary Digital Content 1, http://links.lww.com/
CTG/A737). We collected information on the number of dispensations, the cumulative number of days prescribed, as well as
the cumulative deﬁned daily dose, ATC class of antibiotics
(penicillins, cephalosporins, macrolides, quinolones, tetracyclines, sulfonamides, and other), bacterial target (aerobic vs anaerobic microbes), and spectrum of coverage (broad vs narrow).
We obtained data on level of education (#9 years, 10–12 years,
$13 years, and unknown) from Statistics Sweden and the longitudinal integrated database for health insurance and labor
market studies (28). This information is available for more than
VOLUME 13 | JANUARY 2022 www.clintranslgastro.com
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Figure 1. Flowchart of participant selection. EOCRC, early-onset colorectal cancer; ESPRESSO, Epidemiology Strengthened by histoPathology Reports in
Sweden.

98% of all working-age individuals. We also calculated the
number of inpatient and outpatient encounters (continuous) for
each participant during the study period up until the censoring
date (6 months before the time of matching). We used validated
procedure codes to identify the number of previous lower endoscopies, including colonoscopy (9011, 9023, 4688, 4689, 4674,
4684, UJF32, and UJF35) and sigmoidoscopy (9012, 4685, UJF42,
and UJF45), also accrued until 6 months before match. Consistent
with previous validated methods using ICD codes (31–33), we
calculated Charlson Comorbidity Index (CCI) scores, an established composite measure of overall health and predictor of 10year mortality (33).
Statistical analysis

To evaluate the association between antibiotic therapy and risk of
EOCRC, we performed conditional logistic regression to estimate
crude and multivariable-adjusted odds ratios (aORs) and 95%
conﬁdence intervals (CIs) conditioned on matching criteria (age, sex,
calendar year at the time of match, and county of residence) and
further adjusted for potential confounding factors (number of previous lower endoscopies, educational attainment, and health care
utilization). Tests for linear trend were calculated using the midpoint
of each frequency category as a continuous variable. Two-sided P
values of ,0.05 were considered statistically signiﬁcant.
As a secondary analysis, we assessed antibiotics and risk of CRC
regardless of age. We also performed subgroup analyses according to
the spectrum of antibiotic coverage (broad vs narrow), whether they
targeted aerobic or anaerobic bacteria, class of antibiotic therapy
prescribed (penicillins, tetracyclines, quinolones, macrolides, sulfonamides and trimethoprim, cephalosporins, other nonpenicillin
beta-lactams, and other), and anatomic location of EOCRC. Statistical analyses were performed using R 4.0.1 (Vienna, Austria).

publication. All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.

RESULTS
We identiﬁed 154,317 individuals aged $18 years in the
ESPRESSO study with GI tract biopsies or surgical specimens

Table 1. Characteristics of colorectal cancer cases before age 50
years and controls at the index dates, 2006–2016
Cases
(n 5 2,557)

Controls
(n 5 12,640)

42.9 (6.0)

42.9 (6.1)

1,182 (46.2)

5,866 (46.3)

2006–2007

438 (17.1)

2,173 (17.1)

2008–2010

722 (28.2)

3,577 (28.2)

2011–2013

782 (30.6)

3,877 (30.6)

$2014

615 (24.1)

3,047 (24.0)

284 (11.0)

1,423 (11.3)

1,280 (50.1)

6,216 (49.0)

968 (37.9)

4,835 (38.1)

Age, yr
Female, %
Year of diagnosis, %

Educational attainment
#9 yr
10–12 yr
$13 yr
Unknown
Number of previous clinic visits

25 (1.0)

200 (1.6)

9.7 (16.2)

7.0 (12.4)

Number of previous hospitalizations

3.6 (5.5)

2.8 (4.8)

Number of previous lower endoscopies

0.2 (1.3)

0.02 (0.17)

Charlson Comorbidity Index

0.2 (0.9)

0.1 (0.5)

Role of funding sources

Sponsors had no role in study design, the collection, analysis, and
interpretation of data, report writing, or the decision to submit for
American College of Gastroenterology

Mean (SD) is shown for continuous variables, and percentage is shown for
categorical variables.
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Table 2. Association between use of oral antibiotics and risk of early-onset colorectal cancer (age , 50 years)
Nonusers

Users

OR (95% CI)

Cases (n)

Controls (n)

Cases (n)

Controls (n)

Model 1a

Model 2b

1,141

6,091

1,416

6,583

1.18 (1.07, 1.29)

1.06 (0.96, 1.17)

Broad spectrum

1768

9,330

789

3,344

1.27 (1.15, 1.40)

1.13 (1.02, 1.26)

Narrow spectrum

1,395

7,186

1,162

5,488

1.10 (1.01, 1.21)

1.01 (0.92, 1.11)

All antibiotics
Spectrum of coverage

Bacterial target
Antiaerobic

1,171

6,244

1,386

6,430

1.18 (1.07, 1.29)

1.07 (0.96, 1.17)

Antianaerobic

2,258

11,414

299

1,260

1.21 (1.05, 1.38)

1.01 (0.87, 1.17)

1,481

7,550

1,076

5,124

1.08 (0.98, 1.18)

1.00 (0.91, 1.10)

ATC class
Penicillin
Tetracyclines

2,118

10,722

439

1952

1.15 (1.02, 1.29

1.04 (0.92, 1.18)

Quinolones

2,343

11,952

214

722

1.52 (1.29, 1.78)

1.17 (0.98, 1.40)

Macrolides

2,338

11,636

219

1,038

1.05 (0.90, 1.22)

0.88 (0.75, 1.04)

Sulfonamides and trimethoprim

2,453

12,213

104

461

1.13 (0.91, 1.41)

0.95 (0.75, 1.21)

2,412

12,066

145

608

1.20 (0.99, 1.44)

1.08 (0.88, 1.32)

2,462

12,230

95

444

1.08 (0.85, 1.36)

0.92 (0.72, 1.18)

Cephalosporins and other nonpenicillin
Beta-lactams
Other

Bold text indicates P value ,0.05.
ATC, Anatomic Therapeutic Chemical CI, confidence interval; OR, odds ratio.
a
Conditional logistic regression was used with matching for age (continuous), sex (binary), calendar year at the time of match, and county of residence.
b
Multivariable conditional logistic regression models were further adjusted for education (9 years or less, 10–12 years, $13 years, and missing), number of clinic visits
(continuous), number of hospitalizations (continuous), Charlson Comorbidity Score (continuous), and number of previous lower endoscopies (continuous).

consistent with the diagnosis of EOCRC. After excluding patients
with CRC-compatible tissue or a relevant CRC ICD diagnosis
code before study baseline, as well as individuals without adequate exposure time using our prespeciﬁed lead-in period, we
enrolled 54,804 cases of CRC (of whom, 2,557 were incident
EOCRC) and 261,089 matched controls between January 1, 2006,
and December 31, 2016.
As expected, EOCRC cases were comparable to their matched
controls on the basis of mean age (42.9 years) and sex (46%
female) (Table 1). Cases had higher levels of health care engagement in both the inpatient and outpatient settings, although
notably, CCI scores were grossly comparable. CRC cases diagnosed at any age (and their matched controls), as expected,
were older than those in the EOCRC analysis, and trends in health
care utilization and CCI were comparable (see Supplementary
Table 3, http://links.lww.com/CTG/A737).
Compared with no previous use, any antibiotic use was associated with an 18% increased risk of EOCRC (OR 1.18, 95% CI:
1.07, 1.29; Table 2). However, this ﬁnding was signiﬁcantly attenuated after further adjustment for CCI, number of previous
lower endoscopies, health care engagement, and educational
attainment (aOR 1.06, 95% CI: 0.96, 1.17). The modest increase in risk was found to be statistically signiﬁcant among
previous users of broad-spectrum antibiotics (aOR 1.13, 95%
CI: 1.02, 1.26). No clear association according to aerobic or
antiaerobic coverage or anatomic therapeutic chemical (ATC)
subclass was identiﬁed.
We observed no clear association between the frequency of
antibiotic dispensation and risk of EOCRC (Table 3). A sensitivity
Clinical and Translational Gastroenterology

analysis using cumulative number of days prescribed and the
cumulative deﬁned daily dose did not materially alter our ﬁndings
(data not shown). No signiﬁcant heterogeneity was observed in
risk for EOCRC with previous use of any antibiotics by coverage
or target when we conducted stratiﬁed analyses by tumor location
(Table 4).
When we assessed the link between antibiotics and CRC diagnosed at any age, previous antibiotic therapy was associated
with risk of CRC, demonstrating modestly elevated risk for any
vs no previous use of antibiotics, particularly for broad spectrum (any vs no previous use: aOR 1.05, 95% CI: 1.03, 1.07).
Risk did not seem to be signiﬁcantly elevated for narrowspectrum antibiotics and antianaerobic coverage, although
users of several common classes of antibiotics, including penicillins and tetracyclines, had slight increases in risk compared
with nonusers (see Supplementary Table 4, Supplementary Digital Content 1, http://links.lww.com/CTG/A737).

DISCUSSION
In a population-based case-control study of over 50,000 cases of
CRC, among whom more than 2,500 were diagnosed before age
50 years, antibiotic usage was not convincingly associated with
risk of EOCRC with the possible exception of broad-spectrum
antibiotic usage. However, we did not observe a clear dosedependent relationship between broad-spectrum antimicrobials
and EOCRC, and this result should be interpreted with caution.
In addition, we reaﬃrmed previous evidence demonstrating an
association between antibiotic use and CRC diagnosed at any
age (34).
VOLUME 13 | JANUARY 2022 www.clintranslgastro.com
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No previous use

1 previous
dispensation

2 previous
dispensations

3-5 previous
dispensations

‡6 previous
dispensations

1,141

518

342

363

193

P for trend

All antibiotics
No. of cases
No. of controls

6,091

2,606

1,444

1716

817

OR (95% CI)a

1 (ref)

1.05 (0.93, 1.18)

1.19 (1.03, 1.37)

1.04 (0.90, 1.21)

0.93 (0.76, 1.14)

0.68

Spectrum of
coverage
Broad spectrum
No. of cases

1768

417

181

138

53

No. of controls

9,330

1817

766

578

183

OR (95% CI)a

1 (ref)

1.19 (1.05, 1.35)

1.14 (0.95, 1.37)

1.06 (0.86, 1.31)

0.76 (0.52, 1.11)

0.42

Narrow spectrum
No. of cases

1,395

554

283

253

72

No. of controls

7,186

2,713

1,232

1,198

345

OR (95% CI)a

1 (ref)

1.01 (0.90, 1.13)

1.11 (0.95, 1.29)

0.97 (0.82, 1.15)

0.82 (0.61, 1.10)

0.72

Bacterial target
Antiaerobic
No. of cases

1,171

561

309

361

155

No. of controls

6,244

2,725

1,424

1,604

677

OR (95% CI)a

1 (ref)

1.07 (0.95, 1.20)

1.07 (0.92, 1.25)

1.11 (0.96, 1.28)

0.89 (0.71, 1.11)

0.66

Antianaerobic
No. of cases

2,258

221

43

24

11

No. of controls

11,414

940

211

96

13

OR (95% CI)a

1 (ref)

1.06 (0.90, 1.25)

0.84 (0.59, 1.19)

0.86 (0.51, 1.44)

0.63 (0.20, 2.00)

0.49

Bold text indicates P value ,0.05.
CI, confidence interval; OR, odds ratio.
a
Multivariable conditional logistic regression was used with matching for age (continuous), sex (binary), calendar year at the time of match, and county of residence and
adjusted for education (9 years or less, 10–12 years, $13 years, and missing), number of clinic visits (continuous), number of hospitalizations (continuous), Charlson
Comorbidity Score (continuous), and number of previous lower endoscopies (continuous).

Our results warrant further discussion in the context of previous work in this area. A recent investigation linked antibiotic
usage and colorectal carcinogenesis using a similar nationally
representative matched case-control design but was unable to
fully interrogate the relationship between antibiotics and
EOCRC, as Zhang et al. (34) speciﬁcally excluded individuals
aged ,40 years. In addition, previous studies have not only
demonstrated that life-course antibiotics may be associated with
the development of colorectal adenomas (35)—the most common precursor lesions to both EOCRC (36) and CRC at any age
(37)—but some antibiotic subclasses may be linked to colorectal
precursor lesions in individuals aged ,50 years (38). Furthermore, our ﬁndings of a modest association between antibiotic
usage and later-onset CRC with null results for EOCRC may
reﬂect an inﬂection point for what has been a relatively recent and
successful Swedish public health campaign encouraging antibiotic stewardship and more restrained prescribing practices
(23–25). Whether this public health eﬀort can reverse alarming
trends in EOCRC risk remains to be seen.
The lack of a clear relationship between antibiotics and early
tumorigenesis could suggest that certain antibiotics may be
American College of Gastroenterology

associated with the development of precursor lesions, but not
their acceleration through the adenoma-carcinoma sequence
through which most EOCRCs arise. Conversely, a longer
induction/latency period or time at risk and more granular information related to the timing of antibiotic exposure (e.g., during
childhood) may be required to capture the potentially elevated
EOCRC risk conferred on individuals using antibiotics, a potential explanation for our null ﬁndings.
This investigation was strengthened by the inclusion of all
consecutive eligible patients with new-onset EOCRC from a
population-based register over a 10-year study period. In Sweden,
medication coverage is universal with virtually complete information on dispensations, including antibiotics, minimizing
ascertainment bias (,0.3% of all prescriptions lack identifying
information) (39). We used stringent outcome ascertainment,
requiring both compatible histopathologic ﬁndings and conﬁrmatory ICD coding for cases adjudication. We considered the
possibility of reverse causation (therapy initiated for undiagnosed CRC) or confounding by indication (therapy initiated
for GI infections/bacterial translocation related to new CRC)
and attempted to mitigate this possibility by accounting for
Clinical and Translational Gastroenterology
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Table 4. Association between use of oral antibiotics and risk of early-onset colorectal cancer (age , 50 years) by anatomic location
Nonusers

Users

Cases (n)

Controls (n)

92

481

Broad spectrum

152

778

Narrow spectrum

113

578

Antiaerobic

94

496

Antianaerobic

194

968

OR (95% CI)
Controls (n)

Model 1a

Model 2b

587

1.14 (0.83, 1.57)

0.99 (0.71, 1.39)

66

290

1.18 (0.84, 1.64)

0.94 (0.65, 1.35)

105

490

1.11 (0.82, 1.52)

1.04 (0.75, 1.45)

124

572

1.17 (0.85, 1.61)

1.01 (0.72, 1.42)

24

100

1.21 (0.74, 1.96)

0.79 (0.45, 1.41)

852

1.11 (0.85, 1.45)

1.05 (0.79, 1.39)

Cases (n)
Proximal colon

All antibiotics

126

Spectrum of coverage

Bacterial target

Distal colon
All antibiotics

131

685

178
Spectrum of coverage

Broad spectrum

210

1,088

99

449

1.15 (0.88, 1.53)

1.12 (0.84, 1.50)

Narrow spectrum

157

831

152

706

1.15 (0.88, 1.50)

1.08 (0.81, 1.43)

Antiaerobic

134

698

175

839

1.11 (0.85, 1.44)

1.04 (0.79, 1.38)

Antianaerobic

264

1,353

45

184

1.26 (0.87, 1.80)

1.13 (0.77, 1.66)

2,380

1.12 (0.96, 1.31)

1.04 (0.88, 1.22)

Bacterial target

Rectal
All antibiotics

424

2,198

506
Spectrum of coverage

Broad spectrum

659

3,386

271

1,192

1.18 (1.00, 1.38)

1.06 (0.90, 1.26)

Narrow spectrum

524

2,589

406

1989

1.01 (0.87, 1.18)

0.93 (0.79, 1.09)

Antiaerobic

437

2,247

493

2,331

1.10 (0.94, 1.28)

1.01 (0.86, 1.19)

Antianaerobic

824

4,133

106

445

1.20 (0.95, 1.50)

0.98 (0.77, 1.26)

Bacterial target

CI, confidence interval.
a
Conditional logistic regression was used with matching for age (continuous), sex (binary), calendar year at the time of match, and county of residence.
b
Multivariable conditional logistic regression models were further adjusted for education (9 years or less, 10–12 years, $13 years, and missing), number of clinic visits
(continuous), number of hospitalizations (continuous), Charlson Comorbidity Score (continuous), and number of previous lower endoscopies (continuous).

prescriptions at least 6 months before diagnosis. Thus, we can be
more conﬁdent that antibiotic usage was not likely due to undiagnosed CRC. Finally, our conservative coding of the date of
diagnosis (at the time of either the earliest EOCRC-compatible
histopathology or ICD coding) further minimizes the time period
for which antibiotic dispensations could be attributable to
symptoms of CRC.
We acknowledge limitations. As with all large-scale pharmacoepidemiologic studies, medication dispensation through the
Swedish Prescribed Drug Register may not capture actual usage,
although because of the short-term nature of most antibiotics and
the presumption that dispensations were most frequently attributable to positive symptoms suggestive of an infection, adherence was not likely a major issue or subject to diﬀerential
misclassiﬁcation by case/control status. We did not capture route
of antibiotic administration (intravenous, oral, or other), which
several prehuman investigations have suggested could diﬀerentially inﬂuence gut microbial communities (40,41), although
most exposed patients would have received oral antibiotics in this
prescription database. In addition, the Prescribed Drug Register
Clinical and Translational Gastroenterology

was not established until 2005, limiting the window for exposure
assessment, including the use of antibiotics during childhood—
especially early life—a time of critical importance in the development of gut microbial plasticity and resilience (42–44).
Finally, given the observational nature and epidemiologic scale of
this registry-level investigation, the possibility of unmeasured
confounding remains, including more detailed information on
the presence of familial CRC syndromes and more established
lifestyle risk factors for CRC such as diet (45), alcohol, sedentary
behavior and physical activity (11), and obesity (10), although
none are clearly linked to established diﬀerences in antibiotic
dispensation patterns.
In this prospective population-scale case-control study, previous antibiotic usage was not associated with an increase in the
risk of EOCRC, despite other investigations previously linking
their use to CRC diagnosed at older ages. Subgroup analyses
demonstrated a potential link between broad-spectrum antibiotics and only a small but statistically signiﬁcant elevation of risk
for CRC at any age, the latter being consistent with previous
investigations. These ﬁndings, as well as heterogeneous risk
VOLUME 13 | JANUARY 2022 www.clintranslgastro.com

estimates based on antibiotic class and coverage, should be contextualized by our observation that even statistically signiﬁcant
diﬀerences were modest in magnitude and, thus, of unclear
clinical importance. Our results will need to be validated in other
populations given Sweden’s lower antibiotic dispensation patterns compared with other nations (46), and although these results may be reassuring on some level, antibiotic stewardship and
prescriber restraint should be practiced regardless, particularly
for broad-spectrum antibiotics.
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Study Highlights
WHAT IS KNOWN

3 Early-onset colorectal cancer (CRC) before age 50 years is
rising.

3 Antibiotic use has been linked to CRC after age 50 years, but
no study has focused on early-onset CRC.

WHAT IS NEW HERE

3 Overall antibiotic use was not associated with early-onset CRC
risk.

3 A possible link between broad-spectrum antibiotic use and
early-onset CRC was observed.
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